Delving into the Latest Updates on Vandetanib with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine, Vandetanib (JAN/USAN/INN)

+ [18]

Target

BRK x Eph x RET x Tie-2

Action

inhibitors, antagonists

Mechanism

BRK inhibitors(Tyrosine-protein kinase BRK inhibitors), Eph inhibitors(Ephrin receptor inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors)

Therapeutic Areas

NeoplasmsEndocrinology and Metabolic DiseaseOther Diseases+ [1]

Active Indication

RET Mutation-Positive Medullary Thyroid CancerAdvanced Thyroid Gland Medullary CarcinomaMetastatic Thyroid Gland Medullary Carcinoma+ [3]

Inactive Indication

Advanced biliary tract cancerAdvanced breast cancerAdvanced Colorectal Adenocarcinoma+ [62]

Originator Organization

AstraZeneca Pharmaceuticals Co. Ltd.

Active Organization

Genzyme Corp.AstraZeneca AB

North Sichuan Medical College

+ [6]

Inactive Organization

AstraZeneca PLC

Celgene Corp.

Dana-Farber Cancer Institute, Inc.

License Organization

AstraZeneca PLC

Esteve Pharmaceuticals SA

Genzyme Corp.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (06 Apr 2011),

Thyroid Cancer, Medullary

RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Molecular FormulaC22H24BrFN4O2

InChIKeyUHTHHESEBZOYNR-UHFFFAOYSA-N

CAS Registry443913-73-3

Participants will have been diagnosed with advanced progressive thyroid cancer and are about to start treatment with a tyrosine kinase inhibitor (TKI).
The purpose of this study is to evaluate the efficacy and tolerability of tyrosine kinase inhibitor therapy (Lenvatinib or Sorafenib for differentiated thyroid cancer [which includes papillary thyroid cancer, follicular thyroid cancer, and poorly differentiated thyroid cancer]; and Cabozantinib or Vandetanib for medullary thyroid cancer) through adaptive (intermittent) versus conventional (continuous) regimen.

Start Date06 Aug 2018

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

100 Clinical Results associated with Vandetanib

Login to view more data

100 Translational Medicine associated with Vandetanib

Login to view more data

100 Patents (Medical) associated with Vandetanib

Login to view more data

1,472

Literatures (Medical) associated with Vandetanib

01 May 2026·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Calpain inhibition preserves myofilament integrity and prevents vandetanib–induced cardiac dysfunction

Article

Author: Huang, Jie ; Yan, Jie ; Lu, Jian ; Wu, Lin ; Lu, Lin ; Lv, Si ; Ji, Fang ; Liao, Bin ; Gu, Yinshan ; Xie, Bingbin ; Wen, Hu ; Li, Miaoling ; Yuan, Huan

Vandetanib is a novel multi-targeted tyrosine kinase inhibitor (TKI) that has demonstrated clinical efficacy in the long-term treatment of medullary thyroid carcinoma. However, its use is frequently associated with cardiovascular side effects, some of which may be life-threatening. Notably, multi-targeted TKIs have been increasingly implicated in the risk of cardiotoxicity. Among these, cardiac contractile dysfunction has emerged as a critical concern, yet the underlying mechanisms remain incompletely elucidated-particularly the phenomenon of excitation-contraction uncoupling. This study aims to investigate how vandetanib affects cardiac contractility, with a specific focus on sarcomeric protein degradation, and to identify potential molecular targets for reversing myofilament degradation. Chronic treatment with vandetanib led to a significant reduction in myocardial contractile function, the disruption of cardiac troponin T (cTnT), cardiac troponin I (cTnI) organization and downregulation of essential myofilament proteins, including cTnT (42.3% ± 5.6% protein loss)and MYOM1 (32.7% ± 4.9% protein loss), without notable suppression of calcium-handling proteins such as JPH2, p-PLN, and p-CaMKII. Calcium imaging revealed preserved sarcoplasmic reticulum (SR) calcium release, suggesting contractile dysfunction was not primarily calcium-driven. Instead, reduced myofilament calcium sensitivity and partial sarcomere disassembly were observed. Mechanistically, we identified upregulation of calpain expression and enzymatic overactivation as key mediators of sarcomeric protein degradation. Inhibition of calpain activity partially rescued vandetanib-induced loss of contractile proteins and preserved myofilament structure. Calpain1 overexpression aggravated, while calpain1 knockdown partially rescued, vandetanib-induced cTnT degradation. Our findings uncover a novel mechanism underlying TKI-induced cardiotoxicity, involving calpain-dependent degradation of cardiac myofilament proteins and independent of calcium dysregulation. This study highlights the critical role of sarcomere stability in maintaining cardiac function during TKI therapy and identifies calpain as a promising therapeutic target for cardioprotection, with calpain activation rather than calcium dysregulation being the key driver of vandetanib-induced cardiac dysfunction.

01 Mar 2026·ESMO Open

Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET

Article

Author: Schneegans, O ; Khanal, M ; Illouz, F ; Borget, I ; Benisvy, D ; Varnier, R ; Hernando, J ; Do Cao, C ; Li, X ; Buffet, C ; Zheng, S ; Nascimento, C ; Hadoux, J ; Singh, R ; Lasolle, H ; Tian, W ; Houot, B ; Segall, G ; Hescot, S ; Afonso, A S ; Muller, M ; Zanetta, S ; Wong, K H ; Drui, D ; Roudaut, N

BACKGROUND:

The single-arm phase I/II LIBRETTO-001 trial demonstrated durable efficacy with selpercatinib in patients with rearranged during transfection (RET)-mutation-positive medullary thyroid cancer (MTC). RECALIB-RET compared effectiveness outcomes using a real-world external control (EC) arm of patients with RET-mutation-positive MTC treated with standard of care (SoC) versus selpercatinib (LIBRETTO-001).

PATIENTS AND METHODS:

In this retrospective study, the selpercatinib arm comprised first-line (1L) or second-and-later-line (≥2L) patients from LIBRETTO-001. The EC arm comprised SoC-treated patients, pooled across (i) the French ENDOCAN-TUTHYREF (Refractory Thyroid Tumours) database (1L and ≥2L); (ii) a chart review of European patient medical records (1L and ≥2L) and (iii) a published United States chart review (≥2L). Index treatment was cabozantinib or vandetanib (1L) and any SoC (≥2L; including multikinase inhibitor, chemotherapy or immunotherapy). The primary endpoint was progression-free survival (PFS). The safety profile of SoC in the EC arm was a secondary endpoint. Propensity score matching (PSM) balanced baseline characteristics between treatment arms.

RESULTS:

Baseline characteristics of the 1L selpercatinib (n = 116) and EC (n = 107) arms were balanced; PSM reduced the sample size by <30% across arms (n = 84 per arm after PSM). 1L selpercatinib conferred statistically significant PFS benefit over SoC both pre-PSM [median: not reached (NR) versus 24.0 months; P < 0.001] and post-PSM (median: NR versus 26.1 months; P < 0.001). In ≥2L (selpercatinib, n = 179; EC, n = 51), PSM increased attrition, reducing sample sizes by 78.8% (selpercatinib) and 25.5% (EC), to n = 38 per arm. The unadjusted median PFS was significantly longer with ≥2L selpercatinib versus SoC (35.6 months versus 11.6 months; P = 0.005); the difference did not reach significance after PSM. Safety findings were consistent with previously reported findings for SoC.

CONCLUSION:

Selpercatinib conferred significant PFS benefit over SoC in treatment-naïve (1L) patients with RET-mutation-positive MTC, with inconclusive results in the ≥2L setting. Matching retrospective real-world data to prospective trial data is feasible. EC arms to single-arm trials may provide evidence supporting the evaluation of comparative effectiveness.

01 Feb 2026·Expert Opinion On Drug Safety

Mining and analysis of adverse event signals of vandetanib based on the FAERS database

Article

Author: Yin, Rui ; Chen, Jie ; Liu, Jiang ; Yue, Wenxi ; Zhou, Ying ; Su, Ning ; Ma, Guowei ; Li, Na

OBJECTIVE:

By analyzing the signal mining of vandetanib AEs, it provides a reference for the rational clinical use of the drug.

METHODS:

This study provides signal detection and analysis of AEs associated with vandetanib using the FAERS from Q2 2011 to Q1 2023.

RESULTS:

Disproportionality analyses were conducted using the ROR and the MHRA method, with AEs categorized and described based on SOC and PT from the MedDRA. A total of 1,721 AEs reports identified vandetanib as the primary suspect. The analyses yielded 187 AEs signals across 20 SOCs categories, with 47 signals not previously reported in the vandetanib labeling. Additionally, the study analyzes factors influencing AEs. The results are as follows: There are significant differences in Investigations based on gender and nationality (p < 0.05); skin and subcutaneous tissue disorders and gastrointestinal disorders exhibit differences based on gender, age, and nationality (p < 0.05).

CONCLUSION:

Common AEs signals identified align with those documented in the drug labeling. However, AEs such as tumor lysis syndrome, skin discoloration, and pigmentary disorders, which are not listed in the labeling, warrant special attention. It is essential that abnormalities in patients' skin and laboratory indicators are closely monitored and addressed promptly to safeguard medication safety.

24

News (Medical) associated with Vandetanib

25 Sep 2025

·www.einpresswire.com

FDA Removes Risk Evaluation and Mitigation Strategies (REMS) for Caprelsa (vandetanib)

FDA News Release Agency determines special restrictions are no longer necessary to ensure the benefits of thyroid cancer treatment with Caprelsa outweigh its risks For Immediate Release: September 25, 2025 The U.S. Food and Drug Administration today removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Genzyme Corporation (now Sanofi). The FDA first approved Caprelsa in 2011 to treat medullary thyroid cancer in patients whose disease has spread or cannot be surgically removed. At the time, a REMS program was required to ensure appropriate heart rhythm monitoring and safe use. After over more than a decade of oversight, REMS assessments reported no cases of Torsades de pointes or unexplained sudden deaths among U.S. patients taking Caprelsa. Clinical data also showed no concerning patterns of heart rhythm problems. “Cancer specialists now have adequate knowledge about managing the heart rhythm related risks of this medication,” said Richard Pazdur, M.D., FDA Oncology Center of Excellence Director . “Health care providers have incorporated proper safety monitoring into their standard practice, making the formal requirements unnecessary. The mandatory monitoring program has achieved its goals.” Caprelsa will remain available with the same prescribing information, but health care providers will no longer need special certification or extra monitoring beyond standard clinical care. A REMS is a safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. The safety requirements for Caprelsa included mandatory training for health care providers and monitoring of patients. Contact Information: Health care providers, pharmacies, and patients with questions may contact the FDA at (855) 543-3784 or (301) 796-3400, or by email at druginfo@fda.hhs.gov . Adverse events, medication errors, or quality problems with Caprelsa should be reported to FDA's MedWatch Adverse Event Reporting program. FDA's top priority is patient safety, and the agency will continue to monitor the safety of this medication. ### Boilerplate The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

25 Sep 2025

·www.drugs.com

FDA Removes Risk Evaluation and Mitigation Strategies (REMS) for Caprelsa (vandetanib)

Audience: Patient, Pharmacy, Health Care Professional September 25, 2025 -- The U.S. Food and Drug Administration today removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa ( vandetanib ), a thyroid cancer medication manufactured by Genzyme Corporation (now Sanofi). The FDA first approved Caprelsa in 2011 to treat medullary thyroid cancer in patients whose disease has spread or cannot be surgically removed. At the time, a REMS program was required to ensure appropriate heart rhythm monitoring and safe use. After over more than a decade of oversight, REMS assessments reported no cases of Torsades de pointes or unexplained sudden deaths among U.S. patients taking Caprelsa. Clinical data also showed no concerning patterns of heart rhythm problems. “Cancer specialists now have adequate knowledge about managing the heart rhythm related risks of this medication,” said Richard Pazdur, M.D., FDA Oncology Center of Excellence Director . “Health care providers have incorporated proper safety monitoring into their standard practice, making the formal requirements unnecessary. The mandatory monitoring program has achieved its goals.” Caprelsa will remain available with the same prescribing information, but health care providers will no longer need special certification or extra monitoring beyond standard clinical care. A REMS is a safety program that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. The safety requirements for Caprelsa included mandatory training for health care providers and monitoring of patients. Contact Information: Health care providers, pharmacies, and patients with questions may contact the FDA at (855) 543-3784 or (301) 796-3400, or by email at druginfo@fda.hhs.gov. Adverse events, medication errors, or quality problems with Caprelsa should be reported to FDA's MedWatch Adverse Event Reporting program. FDA's top priority is patient safety, and the agency will continue to monitor the safety of this medication. The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. Source: FDA

Drug ApprovalClinical ResultRadiation Therapy

30 Jun 2025

·www.prnewswire.com

ESTEVE to acquire medicine to treat medullary thyroid cancer

Caprelsa® (vandetanib) is a medicine that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer1. This is a new step forward in ESTEVE's international growth journey focused on highly specialized treatments for high unmet medical and patient needs.  BARCELONA, Spain, June 30, 2025 /PRNewswire/ -- ESTEVE has entered into an agreement with Sanofi to acquire Caprelsa® (vandetanib) rights in more than 50 countries, a treatment that is used in adults and children above 5 years of age to treat aggressive and symptomatic medullary thyroid cancer1. Medullary thyroid carcinoma is a type of cancer that starts in the cells in the thyroid gland that produces the hormone calcitonin. This product is a 'protein tyrosine kinase inhibitor' that blocks the activity of enzymes known as tyrosine kinase. Consequently, the medicine reduces the blood supply to the cancer cells, slowing down the cancer's growth1. "Medullary thyroid carcinoma is a rare neuroendocrine tumor that can produce calcitonin from parafollicular cells. The primary treatment is surgery. However, treatments like vandetanib can often slow down or even partially reverse the tumour growth2. We at ESTEVE are proud to join the fighting effort of the patients diagnosed with this carcinoma and their healthcare professionals, with the ambition to continue improving patient's health and lives", confirms José María Giménez-Arnau, Chief Scientific & Medical Officer of ESTEVE.  In April 2024, ESTEVE acquired a business specialized in rare and ultra-rare diseases in the areas of endocrinology and onco-endocrinology, as a step forward towards becoming a highly specialized company. This acquisition added three new medicines to its portfolio addressing endogenous Cushing's syndrome and Adrenocortical Carcinoma.   Furthermore, last month, ESTEVE acquired a license for a biologic product used to treat children and adolescents from 2 to 18 years-old who suffer from severe primary insulin-like growth factor 1 deficiency3. Building on this, the company last month, the company secured an adjuvant therapy considered the standard of care for high-grade, resectable, non-metastatic osteosarcoma in patients between 2 and 30 years of age4. "We are proud to confirm that we are increasing our highly specialized therapies portfolio. Caprelsa® will help us to improve the lives of patients all around the world. This is a step forward in ESTEVE's international journey focused on highly specialized treatments for high unmet medical needs of patients", concludes Jacob Tolstrup, Chief Commercial Officer of ESTEVE. [The completion of the transaction is subject to obtaining customary regulatory clearances]. References Caprelsa | European Medicines Agency (EMA) Medullary Thyroid Cancer | American Thyroid Association Increlex | European Medicines Agency (EMA)   Mepact I European Medicines Agency (EMA) About ESTEVE ESTEVE () is a global pharmaceutical company with a clear purpose: to improve people's lives. Founded in 1929 and headquartered in Barcelona, ESTEVE has a strong international presence with pharmaceutical affiliates in Spain, Portugal, Italy, Germany, France, the UK, and the USA.   ESTEVE is focused on delivering highly specialized treatments that address significant unmet medical needs in several therapeutic areas. In addition, to our innovative pharma business, we offer comprehensive Contract Manufacturing services (CMO), specializing in the production of Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, and China.  ESTEVE's strong commitment to its core values—people matter, transparency, and accountability—remains at the heart of everything it does.  For more information: Irene Simón, Head of Global External Communications & ESG, ESTEVE Tel.+34 934 466 000 – [email protected] Gemma Mestre, External & Digital Communications Manager, ESTEVE Tel.+34 934 466 000 – [email protected] Logo - SOURCE ESTEVE WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionLicense out/in

100 Deals associated with Vandetanib

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06407	Vandetanib	L01XE12	DB05294

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
RET Mutation-Positive Medullary Thyroid Cancer	European Union	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	Iceland	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	Liechtenstein	Sanofi	01 Feb 2023
RET Mutation-Positive Medullary Thyroid Cancer	Norway	Sanofi	01 Feb 2023
Advanced Thyroid Gland Medullary Carcinoma	South Korea	Sanofi-Aventis Korea Co., Ltd.	24 May 2013
Metastatic Thyroid Gland Medullary Carcinoma	South Korea	Sanofi-Aventis Korea Co., Ltd.	24 May 2013
Thyroid Cancer, Medullary	United States	Genzyme Corp.	06 Apr 2011

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	IPR Pharmaceuticals, Inc.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	AstraZeneca AB	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	United States	AstraZeneca Pharmaceuticals Co. Ltd.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	China	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	IPR Pharmaceuticals, Inc.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	Genzyme Corp.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	AstraZeneca AB	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Japan	AstraZeneca Pharmaceuticals Co. Ltd.	17 Sep 2013
Differentiated Thyroid Gland Carcinoma	Phase 3	Brazil	Genzyme Corp.	17 Sep 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03291379 (VEROnA, Pubmed) Manual	Phase 1	Neoplasms	8	Vandetanib-Eluting Radiopaque Embolics	fxbdexyjtx(mpwnndjhas) = There was 1 grade 3 adverse event (AE) before surgery and 18 after surgery; 6 AEs were deemed to be related to BTG-002814. pzpcpmmvey (dvdknygmdf )	Positive	05 May 2022
NCT01934335 (CTgov)	Phase 2	Invasive Mammary Carcinoma	12	Vandetanib (Vandetanib)	phxrgxycyn(mhhbodofgh) = hcjssphwii nvguscapui (gxhljsvadv, 0.08) View more	-	01 Nov 2021
				Placebo (Placebo)	phxrgxycyn(mhhbodofgh) = wboagubunu nvguscapui (gxhljsvadv, 0.05) View more
NCT01586624 (CTgov)	Phase 1	Non-Small Cell Lung Cancer	61	Selumetinib+Vandetanib (Dose Escalation Phase Cohort 1 (Steady State Dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib))	mrmkzttkot = aqhsmovpuw dcalqwimra (biqzyytsbe, vfeixtvuno - bdabrbpets) View more	-	07 Oct 2021
				Selumetinib+Vandetanib (Dose Escalation Phase Cohort 2 (Steady State Dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib))	mrmkzttkot = knkhnrnxji dcalqwimra (biqzyytsbe, pecsmdyjtl - tpdzasxmry) View more
NCT01582191 (Pubmed \| ESMO Open) Manual	Phase 1	HR-positive/HER2-low Solid Tumors	80	vandetanib+everolimus	nfcmdwnklc(kvadvprctk) = gcioxpoesa rzhmedpzyw (llctsxdulv, 3.4 - 7.3) View more	Positive	01 Apr 2021
NCT03291379 (VEROnA, CTgov)	Early Phase 1	Hepatocellular Carcinoma \| Metastatic Colorectal Carcinoma	8	BTG-002814	fvnfnworxq = hackssauba nkphemvahe (egaakpghzv, habznfecec - uhjhjstspv) View more	-	03 Feb 2021
NCT03630120 (CTgov)	Phase 2	Thyroid Cancer, Follicular \| Differentiated Thyroid Gland Carcinoma \| Papillary thyroid cancer ... View more	6	Sorafenib+Lenvatinib (Standard of Care: DTC)	sienaylxrg(wdnukzyqso) = fidijxkbqf ypiqiiqqhd (ovhpgcvynj, wrsitmfbjh - kkpynwiidx) View more	-	22 Jan 2021
				Sorafenib+Lenvatinib (Adaptive Care: DTC)	sienaylxrg(wdnukzyqso) = wtzildnqzy ypiqiiqqhd (ovhpgcvynj, qmnfhmdnee - sziszokduj) View more
NCT01183559 (CTgov)	Phase 1	Esophageal Carcinoma \| Locally Advanced Gastroesophageal Junction Adenocarcinoma	9	External Beam Radiation Therapy (RT)+Carboplatin+Vandetanib+Paclitaxel+FU	xktdpavncd = vcyokremml zgeoirtxdm (frpfuwypyk, qzctxahovf - ypxwkgvzsz) View more	-	22 Jan 2021
NCT01414426 (CTgov)	Phase 2	Squamous cell carcinoma of the oral cavity \| Verrucous Carcinoma \| Precancerous Conditions	20	biopsy+vandetanib (Arm I (Chemoprevention))	ekucwsbpti = xnpjaizals eakngogaso (ujpolfyruu, ltwsyglomm - yulevjyphf) View more	-	14 Jan 2021
				placebo (Arm II (Placebo))	ekucwsbpti = bjrsdlvmcy eakngogaso (ujpolfyruu, qpusabiomw - iakdvhpdox) View more
NCT00514046 (CTgov)	Phase 1/2	Familial Medullary Thyroid Carcinoma \| Multiple Endocrine Neoplasia Type 2b \| Thyroid Cancer, Medullary	17	Vandetanib (All Participants)	woxbmduhnd = sakmifqytu aqufelfkcg (pxdaefivhm, pivpzdtjba - gbalyjcgag) View more	-	22 Dec 2020
				Vandetanib (Vandetanib: First 100 mg/m^2, Then 150 mg/m^2)	bqqrmuptcv = kmjwbakknk gniwelcfcs (mcwbmkfdlt, xtpllwellg - szzxmaqqxz) View more
NCT02530411 (FURVA, ESMO2020)	Phase 2	Estrogen receptor positive breast cancer	165	Vandetanib 300mg + Fulvestrant 500mg	blisaiubnx(pjutoufvun) = bfqovruodh jcqhnqcpnx (cjswnkuqrn ) View more	Negative	18 Sep 2020
				Placebo + Fulvestrant 500mg	blisaiubnx(pjutoufvun) = ylvcvuuivy jcqhnqcpnx (cjswnkuqrn ) View more